Clinical implications of APOBEC3A and 3B expression in patients with breast cancer

• Published in: PloS one Vol. 15; no. 3; p. e0230261
• Main Authors: Kim, Yong-Seok, Sun, Der Sheng, Yoon, Jung-Sook, Ko, Yoon Ho, Won, Hye Sung, Kim, Jeong Soo
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 16.03.2020; Public Library of Science (PLoS)
• Subjects: Alleles; Biological response modifiers; Biology and Life Sciences; Breast cancer; Cancer patients; Cancer research; Care and treatment; Cell cycle; Death; Deletion; Deoxyribonucleic acid; DNA; Enzymes; Epidermal growth factor; Epidermal growth factors; Gene deletion; Gene expression; Genetic aspects; Genomes; Growth factors; Hormones; Immunoassays; Insertion; Interferon; Interferon gamma; Internal medicine; Lymph nodes; Medical research; Medical schools; Medicine; Medicine and Health Sciences; Messenger RNA; Mutation; Oncology; p53 Protein; Phenotypes; Polymerase chain reaction; Polymorphism; Proteins; Research and Analysis Methods; RNA; Surgery; Time; Tumor proteins; Tumors; United States > US; South Korea
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0230261

We aimed to evaluate the expression of APOBEC3A (A3A), 3B (A3B) mRNA, and germline APOBEC3A/B deletion polymorphism in patients with breast cancers and to investigate the correlation between their expressions and clinicopathological characteristics. RNA and DNA samples were extracted from 138 breast cancer tissues and adjacent normal breast tissues. The levels of A3A and A3B mRNA transcripts were determined using quantitative real-time polymerase chain reaction. Insertion and deletion PCR assays were performed to detect the A3B deletion allele. The serum concentrations of soluble programmed death-ligand 1 (sPD-L1) and interferon gamma were determined using enzyme-linked immunosorbent assays. A3B mRNA expression levels were significantly higher in triple-negative breast cancers compared to hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancers. Older age of the patient and high ki-67 expression were associated with increased expression levels of A3A and A3B mRNA. Advanced tumor stage, presence of lymph node involvement, and high histological grade were associated with increased expression levels of A3A mRNA. The APOBEC3A/B deletion allele was found in 77 (55.8%) patients. TP53 and PIK3CA mutations were detected in 62 (44.9%) and 31 (22.5%) patients, respectively. The presence of a PIK3CA mutation was associated with lower A3A mRNA expression levels. There was a weak positive relationship between A3A mRNA expression levels and serum sPD-L1 levels. There was a difference in A3B mRNA expression levels according to breast cancer subtypes, and high levels of A3A and A3B mRNA expressions were associated with an aggressive phenotype. There was a high incidence of APOBEC3A/B deletion allele. Further studies are needed to identify the clinical significance of APOBEC in Asian patients with breast cancer.